Clinical Forums

Two cases highlight the diagnostic challenges of Demodex blepharitis and underscore the unmet need for approved targeted therapies in the United Kingdom.

A panelist discusses how advances in imaging, patient-centered decision-making, and the introduction of NT-501 therapy are redefining the diagnosis and treatment of macular telangiectasia type 2—emphasizing early intervention, personalized care, and practical implementation strategies to optimize visual outcomes.

Experts share real-world strategies for managing geographic atrophy, emphasizing early intervention, individualized imaging-guided treatment, and patient education to slow disease progression and preserve vision.

An experienced clinician discusses the challenges of identifying and managing a common yet often overlooked eyelid condition. She emphasizes a systematic approach to diagnosis, the importance of differentiating it from other ocular surface diseases, and how emerging therapies can transform patient care. Through practical insights and case examples, she demonstrates how accurate detection and targeted treatment can dramatically improve comfort, vision, and quality of life for patients struggling with chronic irritation and inflammation.

A panelist discusses how retina specialists manage geographic atrophy and neovascular age-related macular degeneration by combining clinical trial data, real-world evidence, and patient-centered approaches—including treatment personalization, emerging therapies, disease monitoring, and transparent communication—to optimize outcomes, support adherence, and preserve vision.

An expert discusses evolving best practices in the diagnosis and management of Demodex blepharitis, highlighting collarettes as pathognomonic and sufficient for diagnosis, the importance of targeting high-risk patient groups for treatment, and the promise of a new pharmacologic therapy that shifts care toward a more effective, flexible, and patient-centered approach.

Mark Lobanoff, MD​, discusses how the IC-8 Apthera small aperture intraocular lens functions as a pinhole-based optical system to create extended depth of focus, demonstrates successful salvage of a complicated light adjustable lens case through lens exchange after pinhole testing, and emphasizes the critical importance of controlling central 3-mm zone astigmatism and ensuring nighttime pupil size remains under 5 mm for optimal visual outcomes in keratoconus patients requiring adjunctive photorefractive keratectomy.

Panelists discuss how interventional glaucoma strategies, sustained-release drug delivery implants, and the versatile iDose device advance care by enabling earlier treatment, improving adherence, and expanding surgical options for long-term disease control.

Sahar Bedrood, MD, PhD, discusses how glaucoma treatment has evolved from a reactive wait-and-see approach to a more proactive strategy that emphasizes early procedural interventions such as sustained-release implants and minimally invasive surgeries to minimize medication burden and vision loss.

Michael W. Stewart, MD​, discusses how high-dose aflibercept (8 mg) can achieve better anatomical and visual outcomes compared with standard anti-VEGF therapies in patients with treatment-resistant diabetic macular edema and neovascular age-related macular degeneration, demonstrating improved retinal drying and extended treatment durability through 3 detailed clinical cases.

Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF therapies like aflibercept 8 mg and faricimab demonstrate superior efficacy and durability in treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) cases, allowing treatment intervals to extend by 2 to 3 weeks, improving anatomical outcomes, and reducing patient treatment burden compared with first-generation agents.

Christopher E. Starr, MD, discusses how to identify, diagnose, and effectively treat Demodex blepharitis in both preoperative cataract patients and contact lens wearers, highlighting the importance of eradicating these mites using FDA-approved lotilaner ophthalmic solution to improve visual outcomes and quality of life.

An expert discusses how innovative viscoelastic delivery systems are enhancing precision, control, and safety in ophthalmic surgery by improving anterior chamber stability, protecting intraocular structures, and optimizing surgical outcomes.

Steven J. Dell, MD discusses how managing cataract surgery in post-refractive surgery patients presents unique challenges including accurate IOL power calculation, epithelial healing variability, and the need for specialized approaches such as piggyback IOLs and careful lens selection to meet high patient expectations for spectacle independence.

Ferhina S. Ali, MD, MPH, discusses how emerging treatments and tailored management strategies can improve the care of patients with geographic atrophy in age-related macular degeneration, emphasizing the importance of patient education and individualized treatment plans.

Nikolas JS London, MD, FACS presents two cases, one with a 92-year-old woman with a long history of bilateral nAMD, and one with a 70-year-old man with IDDM.

Talia R. Kaden, MD​, presents multiple patient cases including a case of choroidal neovascularization with polypoidal choroidal vasculopathy, diabetic macular edema, recurrent retinal vein occlusion, and neovascular age-related macular degeneration with persistent subretinal fluid.

Kamran Riaz, MD, presents an overview of enhanced monofocal IOLs and discusses special cases where they could be considered in addition to conventional cataract surgery.

Albert S. Khouri, MD, describes two patient cases with different stages of glaucoma and discusses interventional treatment options, including selective laser trabeculoplasty and various MIGS devices.

Murtaza Adam, MD, reviews the complement-based treatments for geographic atrophy (GA), discusses factors to consider before starting treatment, and shares insights from real-world cases in his practice to guide effective management strategies.

Dr. Carl D. Regillo, MD, FACS, FASRS provides a comprehensive overview of geographic atrophy, covering its diagnosis, current complement-based treatments, and insights from real-world cases in his practice to guide effective management strategies. 

Richard Adler, MD, FACS, reviews thought-provoking patient cases to showcase how the diagnosis and management of dry eye disease can be improved.

David Eichenbaum, MD, FASRS shares successful clinical experiences treating retinal diseases with second generation agents aflibercept 8 mg and faricimab, emphasizing improvements in visual acuity, anatomical features, and quality of life for patients.

Dilsher S. Dhoot, MD shares his experience leading a case-based roundtable discussion on anti-VEGF biosimilars for retinal diseases, highlighting key insights from each patient case.

Dr Dilsher Dhoot shares his experience of using anti-VEGF biosimilars for managing retinal diseases and presents two patient cases where he achieved significant anatomic improvement by using a ranibizumab biosimilar.